Financial support to our organisation – now transformed into further action!

I am pleased that an internationally-led evaluation of Uppsala BIO’s actions and deliverables over the last four years has concluded that we deliver strongly and that we shall receive further solid funding. Planned actions can thus now be executed. The long-term goal is, as always, to contribute to growth by driving actions that complement those of the private and public sectors.

Sweden has a small population so we must pool forces and not fragment resources. This includes the innovation support system, as well as more long-term support to other selected functions. For a growth initiative like Uppsala BIO, a situation of increasingly short-term funding may sometimes hamper more complex actions. Nevertheless, an upside is that we need to show results very frequently. Now further funding both from Vinova and the region is in place. So what more shall we achieve with it?

Uppsala BIO will continue to develop its network. Our Partnership model is in place and the network is growing. In particular, we will continue to work increasingly closely with companies generally ‘too mature’ to be part of innovation support systems such as incubators. Often they may have 10-100 employees and are frequently still part of a ‘death valley’. At this stage, some are open to further investments in the range of, for instance, 30-100 MSEK. We may also have a further role to play, e.g. supporting their needs for match-making with national and international investors. Our dialogue with these companies tells us that we shall try to be more efficient in supporting those who want to grow. Such actions are now being planned. They should increase international competitiveness and lead to further business establishments nationwide. I will come back to this!

At Uppsala BIO, we also support collaboration and coordination among innovation support organisations, not only in our region. Better support for projects and small companies in need of competence, capital and networks nationally will also benefit our region. Such actions include contributing to the strategic innovation programmes Swelife and Medtech4Health. I am a member of the Governing Board of Swelife and staff from Uppsala BIO lead certain programme activities at an operational level, e.g. national calls for proposals. Swelife has already shown good results in strengthening the whole life science ecosystem.

Uppsala BIO also supports the development of infrastructure. A very important task is to contribute to building external processes to support the unique new government-funded BioProcess Innovation Center. The facility is under construction as I write. It’s located in close proximity to GE Healthcare, the world-leading provider of equipment, reagents and support to the global pharmaceutical industry. Without such products there would be no biological pharmaceuticals! And these products are produced at GE Healthcare Life Sciences in Uppsala, Sweden!

From 2018, the BioProcess Innovation Center will have fully-equipped facilities to train students focusing on both technology and biology. Furthermore, projects and companies can gain access to laboratories to test new equipment, new methods and new biologicals in an authentic world-leading manufacturing environment. Uppsala BIO and SWElife are ready to support building external interfaces – because this resource is in principle open to anyone! We have a great track record in building such interfaces and we will, together with our partners, support your efforts!

Wishing you a great autumn! 

Erik Forsberg, 
Managing Director,
Uppsala BIO

Erik Forsberg. Ph.D., Associate Professor, CEO. “My goal is to drive system improvements that create better conditions for life science to develop in Uppsala.”

Contact me
Commentary
Kristin Hellman, Uppsala BIO - 2018-08-22

Uppsala BIO helps Testa Center off to a flying start

Process based on successful BIO-X methodology.

>>

Kristian Sandberg, Director of DDD, SciLifeLab in Uppsala - 2018-08-21

How to bridge the ‘Valley of Death’

The SciLifeLab Drug Discovery Model.

>>

Erik Forsberg, Uppsala BIO - 2018-06-15

“You can make a holding company profitable, but it takes a bit of luck.”

This autumn, Lars Jonsson, CEO of UU Holding since 1998, retires and hands over a very successful investment business to his successor. “UU Holding is nothing short of a success story,” writes Uppsala BIO’s Erik Forsberg. Lars Jonsson has proven that it is possible to make a holding company profitable.

>>

Magnus Engevik, Uppsala BIO - 2018-05-21

Uppsala’s innovation support system works! Award-winning Kontigo Care is the latest proof.

“With its high costs and huge suffering for those affected as well as their relatives, alcohol abuse is one of our major social problems. Kontigo Care’s work on digital biomarkers is one of the most exciting things I’ve witnessed during my career,” writes Uppsala BIO Buiness Developer Magnus Engevik.

>>

Margaretha Gadnell, Uppsala BIO - 2018-04-25

Spotlight Uppsala’s unique resource!

Uppsala’s life science industry is healthy and developing well. More than 100 life science companies can be found here and in 2016 they employed about 5000 people and had a combined turnover of approximately SEK 27 billion.

>>

Christina Wass, Project leader, Innovation Akademiska - 2017-12-13

“What happens in Vegas stays in Vegas…”

During 52 hours, staff from the Academic Hospital, AbbVie, Bristol Myers-Squibb and Microsoft worked together to develop and test new ideas and models for early diagnosis and better treatment of cancer. Now the experiences of Sweden's first “Innovation Race” can be summed up.

>>

Lovisa Case - 2017-11-07

50 years of excellence – it all started with a collaboration between academia and industry!

2017 marks the 50 year anniversary of the RAST-method. Learn about the history and see how Uppsala BIO and UU Innovation are addressing future challenges in asthma and allergy diagnostics.

>>

Johan Gómez de la Torre - 2017-10-25

Sweden needs new regulations and ways for collaboration to stay ahead in healthcare and the life sciences

Challenges and opportunities for countries wanting to take a leading role in life sciences, with focus on the future role of Sweden, was the topic of a seminar in May 2017. In our blog Johan Gómez de la Torre, Business Development Manager, Stockholm Science City digest the report.

>>

Anna Ridderstad Wollberg - 2017-10-16

Call for proposals: A pull to transform inventions into innovations

How do we pull out the good ideas that may become new innovative products or treatments for the benefit of patients? Calls for project proposals may be the pull that is needed.

>>

Madeleine Neil, Uppsala Health Summit - 2017-10-08

Uppsala Health Summit 2017: Time for the world to meet on Infectious Disease Threats  

10 – 11 October Uppsala Health Summit gathered 200 decision makers and experts from 30 different countries in a discussion about global threats from zoonotic infectious diseases. 

>>

Karin Meyer, CEO, Swedish Pharmaceutical Society - 2017-10-02

EMA needs Sweden’s strong scientific environment

Karin Meyer, CEO, Swedish Pharmaceutical Society about what Sweden can offer the EMA and EU.

>>

Margaretha Gadnell, Uppsala BIO - 2017-09-26

Check out EIT Health and its Uppsala activities

The purpose of EIT Health is to accelerate entrepreneurship and innovation for healthy living and active ageing in Europe.

>>

Margareta Gadnell, Uppsala BIO - 2017-09-18

Fast-growing companies in Uppsala’s life science cluster

Between 2014 and 2015, the number of employees in this category increased by 11%. If we include 2013 as well, the increase is almost 20%.

>>

Erik Forsberg, Uppsala BIO - 2017-08-28

Financial support and further action!

Our long-term goal is, as always, to contribute to growth by driving actions that complement those of the private and public sectors.

>>

Annakarin Svenningsson, Uppsala BIO - 2017-08-15

Tough competition prior to relocation of EMA after Brexit

Among the arguments stressed in the Swedish application to convince other member states that Sweden and Stockholm is best suited to host the EMA, is the Swedish Medical Products Agency (MPA) in Uppsala.

>>